ArticleEuropean journal of cancer (Oxford, England : 1990)2020
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR.
Article in European journal of cancer (Oxford, England : 1990), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 15 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 15 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- Risk factors for mortality among lung cancer patients with covid-19 infection: A systematic review and meta-analysis.PloS one · 2023Pooled it
- Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID-19: Results of a systematic review and meta-analysis.Reviews in medical virology · 2022Pooled it
- Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer: A Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- Pooled it
- Pooled it
- Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis.BMJ open · 2022Pooled it
- Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis.Cancer immunology, immunotherapy : CII · 2022Pooled it
- Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis.Critical reviews in oncology/hematology · 2021Pooled it
- Guideline
- COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients.The Journal of infection · 2021Pooled it
- The effect of anticancer treatment on cancer patients with COVID-19: A systematic review and meta-analysis.Cancer medicine · 2021Pooled it
- Pooled it
- A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19.European journal of cancer (Oxford, England : 1990) · 2020Pooled it
- Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies.European journal of cancer (Oxford, England : 1990) · 2020Pooled it
- Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis.Oncoimmunology · 2020Pooled it
- A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.The Journal of clinical investigation · 2021Trial
- Change in Clinical Management of Localized Prostate Cancer Patients at a Tertiary Medical Center as a Result of SARS-CoV-2 (COVID-19).Prostate cancer · 2026Article
- Impact of COVID-19 vaccination on cancer patients: safety, efficacy, and long-term effects.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Review
- Review
- COVID-19 lockdown-related treatment modifications did not impact the outcome of digestive cancers: the Clin-COVIDICA prospective study.BMC cancer · 2025Observational
20 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
40 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer patients presenting with COVID-19 have a high risk of death. In this work, predictive factors for survival in cancer patients with suspected SARS-COV-2 infection were investigated.
methodsPRE-COVID-19 is a retrospective study of all 302 cancer patients presenting to this institute with a suspicion of COVID-19 from March 1st to April 25th 2020. Data were collected using a web-based tool within electronic patient record approved by the Institutional Review Board. Patient characteristics symptoms and survival were collected and compared in SARS-COV-2 real-time or reverse-transcriptase PCR (RT-PCR)-positive and RT-PCR-negative patients.
resultsFifty-five of the 302 (18.2%) patients with suspected COVID-19 had detectable SARS-COV-2 with RT-PCR in nasopharyngeal samples. RT-PCR-positive patients were older, had more frequently haematological malignancies, respiratory symptoms and suspected COVID-19 pneumonia of computed tomography (CT) scan. However, respectively, 38% and 20% of SARS-COV-2 RT-PCR-negative patients presented similar respiratory symptoms and CT scan images. Thirty of the 302 (9.9%) patients died during the observation period, including 24 (80%) with advanced disease. At the median follow-up of 25 days after the first symptoms, the death rate in RT-PCR-positive and RT-PCR-negative patients were 21% and 10%, respectively. In both groups, independent risk factors for death were male gender, Karnofsky performance status <60, cancer in relapse and respiratory symptoms. Detection of SARS-COV-2 on RT-PCR was not associated with an increased death rate (p = 0.10). None of the treatment given in the previous month (including cytotoxics, PD1 Ab, anti-CD20, VEGFR2…) correlated with survival. The survival of RT-PCR-positive and -negative patients with respiratory symptoms and/or COVID-19 type pneumonia on CT scan was similar with a 18.4% and 19.7% death rate at day 25. Most (22/30, 73%) cancer patients dying during this period were RT-PCR negative.
conclusionThe 30-day death rate of cancer patients with or without documented SARS-COV-2 infection is poor, but the majority of deaths occur in RT-PCR-negative patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.